Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 6/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197161 | 0.89 | CNR2 (0.71) | CNR2CNR1PTGS2PTGS1CA1 | |
| Hydrochloric Acid SCHEMBL4576062 | 0.87 | CNR2 (0.69) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1929381 | 0.84 | CNR2 (0.72) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1927472 | 0.84 | CNR2 (0.64) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1928747 | 0.83 | CNR2 (0.71) | CNR2CNR1PTGS2PTGS1CA1 | |
| Hydrochloric Acid SCHEMBL1928223 | 0.83 | CNR2 (0.63) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL9630128 | 0.83 | CNR2 (0.63) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1927474 | 0.81 | CNR2 (0.67) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1926401 | 0.81 | CNR2 (0.67) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL2348536 | 0.81 | CNR2 (1.00) | CNR2CNR1PTGS2PTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207709-A1 | Thiazole Derivatives for Treating Dyskinesias Caused by a Chemical Treatment | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207709-A1 | Thiazole Derivatives for Treating Dyskinesias Caused by a Chemical Treatment | COMT, SLC6A3, PARK7 | CNR2 846/4885LOXL2 3553/4885TAAR1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.